Subject(s)
Bacteremia/microbiology , Gardnerella vaginalis/isolation & purification , Gram-Positive Bacterial Infections/microbiology , Urethritis/microbiology , Adult , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Bacteremia/drug therapy , Ceftriaxone/therapeutic use , Ciprofloxacin/pharmacology , Ciprofloxacin/therapeutic use , Drug Resistance, Multiple, Bacterial , Gardnerella vaginalis/drug effects , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/epidemiology , Humans , Immunocompetence , Male , Metronidazole/therapeutic use , Recurrence , Sex Distribution , Urethritis/diagnosis , Urethritis/drug therapyABSTRACT
The antimicrobial activities of josamycin, erythromycin, and spiramycin against Rickettsia conorii and R. rickettsii were evaluated in two tests: a dye-uptake assay and a plaque assay. The MIC of josamycin was 1 microgram/ml for both species; the MICs of erythromycin and spiramycin were 4 to 8 and 16 to 32 micrograms/ml, respectively, for both species. Only josamycin may be of clinical use in treating spotted fever rickettsiosis. It may be useful in treating pregnant women and young children.
Subject(s)
Erythromycin/pharmacology , Leucomycins/pharmacology , Rickettsia rickettsii/drug effects , Rickettsia/drug effects , Animals , Microbial Sensitivity Tests , Vero CellsABSTRACT
The activity of pefloxacin against Rickettsia conorii and R. rickettsii was determined by several methods. The mean survival time of embryonated eggs infected with R. conorii was increased by pefloxacin 50 micrograms/egg; plaque formation in Vero cells was inhibited by 1 mg/l. In a microplate assay, the MIC of pefloxacin was 0.5 mg/l for R. conorii and 1 mg/l for R. rickettsii. The results support the use of pefloxacin in treating spotted fever rickettsioses.
Subject(s)
Norfloxacin/analogs & derivatives , Rickettsia rickettsii/drug effects , Rickettsia/drug effects , Animals , Chick Embryo , Norfloxacin/pharmacology , Pefloxacin , Rickettsia/growth & development , Rickettsia rickettsii/growth & development , Vero CellsABSTRACT
We tested the susceptibility of Rickettsia conorii to ciprofloxacin, a new quinolone antibiotic. A final concentration of 1 microgram/g of egg was effective in suppressing chicken embryo lethality, and a concentration of 0.25 micrograms/ml inhibited plaque formation in a plaque assay; however, a concentration of 0.5 microgram/ml was necessary to obtain rickettsiacidal activity. These results support the idea that ciprofloxacin could be of clinical use in treating Mediterranean spotted fever.
